Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...

Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.

Many companies and investors believe that AI has to potential to reshape various elements of the pharma industry. Two ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

Direct-to-consumer advertising can be a controversial topic in the pharma industry. While the US isn’t the only other country ...

Paul Howe, chief commercial officer at Protega Pharma, discusses recent rule changes and how the industry is impacted by them ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.